KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Evolent Health (EVH) Asset Writedowns and Impairment (2023 - 2024)

Evolent Health has reported Asset Writedowns and Impairment over the past 2 years, most recently at $2.6 million for Q4 2024.

For Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to $2.6 million; the TTM value through Dec 2024 reached $2.6 million, down 89.25%, while the annual FY2024 figure was $2.6 million, 89.25% down from the prior year.
Asset Writedowns and Impairment for Q4 2024 was $2.6 million at Evolent Health, down from $24.1 million in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $24.1 million in Q2 2023 and troughed at $2.6 million in Q4 2024.